Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02625961
Title Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | FRA

Facility Status City State Zip Country Details
Call for Information (Investigational Site 0023) Recruiting Minneapolis Minnesota 55455 United States Details
Call for Information (Investigational Site 0002) Recruiting Hackensack New Jersey 07601 United States Details
Call for Information (Investigational Site 0018) Recruiting New Brunswick New Jersey 08903 United States Details
Call for Information (Investigational Site 0072) Recruiting Cincinnati Ohio 45212 United States Details
Call for Information (Investigational Site 0009) Recruiting Cleveland Ohio 44106 United States Details
Call for Information (Investigational Site 0074) Recruiting Bala-Cynwyd Pennsylvania 19004 United States Details
Call for Information (Investigational Site 0078) Recruiting Myrtle Beach South Carolina 29572 United States Details
Merck Sharp & Dohme Recruiting North Ryde Australia Details
MSD Finland Oy Recruiting Espoo Finland Details
MSD France Recruiting Paris France Details
MSD Italia S.r.l. Recruiting Rome Italy Details
Merck Sharp & Dohme BV Recruiting Haarlem Netherlands Details
Merck Sharp & Dohme Ilaclari Ltd. Sti Recruiting Istanbul Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field